Clinical trials: Vascular Malformation
Patent Foramen Ovale, Cardiac Implantable Electronic Device
Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Patients with a patent foramen ovale in the setting of endocardially placed cardiac implantable electronic devices such as pacemakers, defibrillators, or resynchronization therapies are likely at higher risk for paradoxical…
- Trial name
- PARADOX (NCT02378623)
- Testing
- Apixaban
- Where
- United States
- Sponsor
- Mayo Clinic
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency
- Trial name
- ENERGY (NCT05734196)
- Testing
- INZ-701
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 9 people
- Sponsor
- Inozyme Pharma
Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease
- Trial name
- NCT02750982
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Fabry Disease
Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI
This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.
- Trial name
- FIESTA-MRI (NCT04856059)
- Testing
- Cardiac MRI, ECG/Holter and Blood Biomarkers
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- University Health Network, Toronto
Fabry Disease
Sophisticated Assessment of Disease Burden in Patients With Fabry Disease
To detect early signs of cardiac and metabolic alterations as well as to evaluate the progression of cardiac and metabolic impairments in mildly affected patients with Fabry Disease using high sensitive diagnostic methods.
- Trial name
- SOPHIA (NCT01210196)
- Testing
- MRI
- Where
- 11 sites in Belgium, Czechia and 4 more
- Volunteers
- 36 people
- Sponsor
- Shire
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Ventricular Septal Defect, Pulmonary Hypertension
The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension
Intraoperative myocardial and pulmonary protection is important for better outcome after cardiac surgery. Ischemic preconditioning is one of organ protective strategies against ischemia-reperfusion injury by applying brief…
- Trial name
- NCT01313832
- Testing
- remote ischemic preconditioning (RIPC)
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Renal Replacement Therapy, Renal Dialysis
A Clinical Trial of IntensiVE Dialysis
This study will assess clinical outcomes of extended weekly hours of haemodialysis (>= 24 hours per week) compared with standard hours of haemodialysis (<=18 hours/week) in people with ESKD.
- Conditions
- Renal Replacement Therapy, Renal Dialysis, End Stage Kidney Disease, End Stage Renal Disease
- Trial name
- ACTIVE (NCT00649298)
- Testing
- haemodialysis
- Where
- 40 sites in Australia, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- The George Institute
Angina Pectoris, Left Ventricular Wall Motion Abnormalities
Intraprocedural Determination of Myocardial Vitality Using 2 Different Imaging Methods
The investigators will compare myocard vitality diagnostics using 2D-Strain echography and MRI.
- Trial name
- NCT01934699
- Testing
- Cardiac ultrasound, MRI scanner
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- RWTH Aachen University
Renal Insufficiency, Chronic, Arteriovenous Fistula
Artificial Intelligence-based Prediction of Radio-cephalic Arteriovenous Fistula Maturation Using Preoperative Duplex Examination
The goal of this observational study is to assess the efficacy of AI-driven models in analyzing comprehensive ultrasonographic variables across multiple forearm locations to predict successful AVF maturation.
- Conditions
- Renal Insufficiency, Chronic, Arteriovenous Fistula, Artificial Intelligence (AI), Machine Learning
- Trial name
- NCT06600750
- Testing
- Arteriovenous fistula
- Where
- South Korea
- Volunteers
- 494 people
- Sponsor
- Seoul National University Hospital
Improve Endothelial Function and Decrease Vascular Stenosis
Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Patients with stage IV and V chronic kidney disease and end stage renal disease requiring hemodialysis at University of Alabama at Birmingham (UAB) Dialysis Clinics will be recruited from the UAB Vascular Access Clinic, which has…
- Trial name
- NCT02414204
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Alabama at Birmingham
Retinitis Pigmentosa, Maculopathy, Age Related
Bimodal and Coaxial High Resolution Ophtalmic Imaging
The knowledge of the pathogenesis of retinal affections, a major cause of blindness, has greatly benefited from recent advances in retinal imaging.
- Conditions
- Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy, Macular Edema
- Trial name
- AOSLO-OCT (NCT04620876)
- Testing
- Bimodal high resolution imaging of the retina
- Where
- France
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Hip Fracture of Intertrochanteric Type, Thromboembolic Event
Diffrence in Thromboprofilaksis in Elderly Ostoepenic Hip Fractures According to Mobility Status by Genetic Analysis
Hip fracture is a common and severe disease in elderly patients. The question of the study is whether elderly patients with severe osteopenia have significantly lower levels of the collagen-binding protein Hsp47 than relatively…
- Conditions
- Hip Fracture of Intertrochanteric Type, Thromboembolic Event, Osteopenia, Thrombosis Embolism
- Trial name
- HSP 47 (NCT06959017)
- Testing
- Gene Expression Analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Hemorrhagic Hereditary Telangiectasia, HHT
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study…
- Trial name
- BEST (NCT06039124)
- Testing
- bevacizumab treatment
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Hospices Civils de Lyon
Fabry Disease
Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease
The goal of this observational study is to learn how enzyme replacement therapy works in patients with Fabry disease. The main question it aims to answer is: What medical problems do participants have? Participants already on…
- Trial name
- FAVORIT (NCT06880250)
- Where
- 23 sites in Russia
- Volunteers
- 100 people
- Sponsor
- NPO Petrovax
Atherosclerosis, Cardiovascular Diseases
Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia
To conduct focused studies of lipoprotein physiology and pathophysiology in genetically characterized patients with the objectives of understanding disease mechanisms, developing better treatments, and identifying and preventing…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Hypercholesterolemia
- Trial name
- NCT00005313
- Volunteers
- 450 people
- Sponsor
- University of Washington
Joint Hypermobility, Ehlers-Danlos Syndrome
Gait Retraining in Patients With Joint Hypermobility Syndrome/Hypermobile Ehlers Danlos Syndrome
This study evaluates the efficacy of gait retraining with biofeedback in the treatment of neuromusculoskeletal symptoms in patients with Joint Hypermobility Syndrome/Hypermobile Ehlers Danlos Syndrome.
- Conditions
- Joint Hypermobility, Ehlers-Danlos Syndrome, Hyperextension Knees
- Trial name
- NCT03575182
- Testing
- Gait retraining program
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Myocardial Bridge
Myocardial Bridge Evaluation Towards Personalised Medicine: the RIALTO Registry
Myocardial bridge (MB) is a congenital anomaly of epicardial circulation characterized by an intramural course of a coronary segment.
- Trial name
- RIALTO (NCT05111418)
- Where
- 5 sites in Italy
- Volunteers
- 444 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Heart Defects, Congenital
Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation
This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt.
- Trial name
- CLARINET LT (NCT00833703)
- Testing
- Clopidogrel
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
Hereditary Hemorrhagic Telangiectasia (HHT), Rendu Osler Disease
IV Bevacizumab Treatment of Patients With Hereditary Hemorrhagic Telangiectasia (HHT) or Rendu-Osler (RO) Disease: A Retrospective Analysis of French Cohort Data From 2009 to 2024
Rendu-Osler disease (RO), also known as Hereditary Haemorrhagic Telangiectasia (HHT), is an autosomal dominant genetic disorder. Its pathophysiology is associated with an imbalance in angiogenic balance.
- Trial name
- CoBé (NCT07772050)
- Testing
- Real World data study.
- Where
- France
- Volunteers
- 244 people
- Sponsor
- Hospices Civils de Lyon